Search

Search Constraints

You searched for: Author/Creator Angelico, M.

Search Results

1. A hyper-glycosylation of HBV surface major hydrophilic region correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro. (15th February 2015)

2. An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets. Issue 1 (16th February 2017)

3. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C. (February 2020)

4. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. (February 2019)

5. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Issue 1 (February 2018)

6. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?. (10th February 2016)

7. Clinical and virological characteristics of HIV and HCV co-infected versus HCV monoinfected patients: A real-life evaluation in the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort. (10th February 2016)

8. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents. (10th February 2016)

9. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. (15th February 2015)

10. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?. Issue 1 (16th February 2017)